Search

Your search keyword '"Mankbadi, Michael"' showing total 16 results
Start Over Author "Mankbadi, Michael"
16 results on '"Mankbadi, Michael"'

2. Variation in Reader-Reported Severity of Paradoxical Low-Flow Low-Gradient Aortic Stenosis

Author

Shah, Nimish N., primary, Sugeng, Lissa, additional, Zhang, Zhiyuan, additional, Wang, Kangxin, additional, McNamara, Robert L., additional, Agarwal, Vratika, additional, Hur, David J., additional, Lombo, Bernardo, additional, Bellumkonda, Lavanya, additional, Mankbadi, Michael, additional, Basem Dajani, Abdel Rahman, additional, Forrest, John K., additional, Krumholz, Harlan M., additional, Reinhardt, Samuel W., additional, Velazquez, Eric J., additional, and Faridi, Kamil F., additional

Published
2023
Full Text
View/download PDF

3. THE INCIDENCE OF CHAGAS CARDIOMYOPATHY IN A NORTHWESTERN COMMUNITY OF CÓRDOBA, ARGENTINA

Author

Martinez, Maria Laura, primary, Amuchastegui, Marcos, additional, Grima, Juan Gonzalez, additional, Amuchastegui, Tomas, additional, Alvarellos, Teresita, additional, McNamara, Katelyn, additional, Garimella, Sanjana, additional, Sánchez, Ariel, additional, Mankbadi, Michael, additional, Sewanan, Lorenzo Rakesh, additional, Salomone, Oscar, additional, McNamara, Robert L., additional, and Lombo, Bernardo, additional

Published
2023
Full Text
View/download PDF

5. ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH KINASE INHIBITORS IN THE TREATMENT OF CANCER REVEAL SPECIFIC RISK BASED ON THE KINASE INHIBITOR - A SINGLE-CENTER RETROSPECTIVE COHORT STUDY

Author

Kwan, Jennifer, primary, Shen, Miles, additional, Mankbadi, Michael, additional, Wang, Peter, additional, Zaman, Saif, additional, Lee, Seohyuk, additional, Jiang, Matthew, additional, Tao, Weiwei, additional, Wei, Wei, additional, and Akhlaghi, Narjes, additional

Published
2022
Full Text
View/download PDF

7. Diversity, Equity, and Inclusion in Hematology and Oncology Fellowship Programs

Author

Mankbadi, Michael, primary, Alemu, Lidet, additional, Bey, Afiya, additional, Connell, Nathan T., additional, Fanning, Lisa, additional, Frustace, Patricia, additional, Genao, Inginia, additional, Hafler, Janet, additional, LaCasce, Ann S., additional, Lucas, Tiffany Lin, additional, Marshall, Ariela L., additional, Mones, Jodi, additional, Murphy, Martina C, additional, Naik, Rakhi P., additional, Podoltsev, Nikolai, additional, and Lee, Alfred Ian, additional

Published
2021
Full Text
View/download PDF

8. PRO-THROMBOTIC SIGNATURE FROM NEUTROPHIL ACTIVATION AND DECREASED ADAMTS13 TO VWF RATIO IS A KEY DRIVER OF CARDIAC INJURY IN HOSPITALIZED PATIENTS WITH COVID-19

Author

Wang, Stephen Yishu, primary, Pine, Alexander B., additional, Mankbadi, Michael, additional, Chang, C. Hong, additional, Madeeva, Daria, additional, Zhang, Hanming, additional, Dajani, Abdel R.B., additional, Crandall, Ian, additional, Sugeng, Lissa, additional, Lee, Alfred I., additional, and Chun, Hyung, additional

Published
2021
Full Text
View/download PDF

9. Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID ‐19: A propensity score‐matched analysis

Author

Meizlish, Matthew L., primary, Goshua, George, additional, Liu, Yiwen, additional, Fine, Rebecca, additional, Amin, Kejal, additional, Chang, Eric, additional, DeFilippo, Nicholas, additional, Keating, Craig, additional, Liu, Yuxin, additional, Mankbadi, Michael, additional, McManus, Dayna, additional, Wang, Stephen Y., additional, Price, Christina, additional, Bona, Robert D., additional, Ochoa Chaar, Cassius Iyad, additional, Chun, Hyung J., additional, Pine, Alexander B., additional, Rinder, Henry M., additional, Siner, Jonathan M., additional, Neuberg, Donna S., additional, Owusu, Kent A., additional, and Lee, Alfred Ian, additional

Published
2021
Full Text
View/download PDF

13. Iron Chelation by Polyamidoamine Dendrimers: A Second-Order Kinetic Model for Metal–Amine Complexation.

Author

Mankbadi, Michael R., Barakat, Mohamed A., Ramadan, Mohamed H., Woodcock, H. Lee, and Kuhn, John N.

Subjects
*IRON, *CHELATION, *POLYAMIDOAMINE dendrimers, *CHEMICAL kinetics, *AMINES, *METAL complexes, *NUCLEAR magnetic resonance spectroscopy
Abstract

This study presents a kinetic model of the chelation of iron ions by generation 4 hydroxyl-terminated polyamidoamine (PAMAM) with ethylenediamine core (G4-OH). The coordination processes of iron ions from ferric chloride, FeCl3, and ferrous bromide, FeBr2, to G4-OH dendrimers were analyzed using ultraviolet–visible (UV–vis) spectroscopy, proton nuclear magnetic resonance (1H NMR) spectroscopy, and liquid chromatography–mass spectrometry (LC–MS). In the visible region, a charge-transfer was observed when the dendrimer was added to a ferric chloride solution. This phenomenon is a ligand-to-metal charge-transfer (LMCT) between the free electron group of the dendrimer’s internal amines and the dehalogenated iron ion that takes 2 h to complete at room temperature. Analysis of potential rate laws and diffusion effects led to a second-order kinetic model for this reaction. By measuring the rate coefficients as a function of temperature (22–37 °C), an apparent activation energy of 41.5 kJ/mol was obtained using the Arrhenius method. The results of this study will fuel research of PAMAM dendrimers for environmental, pharmaceutical, and materials applications. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

16. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis.

Author

Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang S, Price C, Bona RD, Chaar CIO, Chun HJ, Pine AB, Rinder HM, Siner J, Neuberg DS, Owusu KA, and Lee AI

Abstract

Background: Thrombotic complications occur at high rates in hospitalized patients with COVID-19, yet the impact of intensive antithrombotic therapy on mortality is uncertain., Research Question: How does in-hospital mortality compare with intermediate- versus prophylactic-dose anticoagulation, and separately with in-hospital aspirin versus no antiplatelet therapy, in treatment of COVID-19?, Study Design and Methods: Using data from 2785 hospitalized adult COVID-19 patients, we established two separate, nested cohorts of patients (1) who received intermediate- or prophylactic-dose anticoagulation ("anticoagulation cohort", N = 1624), or (2) who were not on home antiplatelet therapy and received either in-hospital aspirin or no antiplatelet therapy ("aspirin cohort", N = 1956). Propensity score matching utilizing various markers of illness severity and other patient-specific covariates yielded treatment groups with well-balanced covariates in each cohort. The primary outcome was cumulative incidence of in-hospital death., Results: Among propensity score-matched patients in the anticoagulation cohort (N = 382), in a multivariable regression model, intermediate- compared to prophylactic-dose anticoagulation was associated with a significantly lower cumulative incidence of in-hospital death (hazard ratio 0.518 [0.308-0.872]). Among propensity-score matched patients in the aspirin cohort (N = 638), in a multivariable regression model, in-hospital aspirin compared to no antiplatelet therapy was associated with a significantly lower cumulative incidence of in-hospital death (hazard ratio 0.522 [0.336-0.812])., Interpretation: In this propensity score-matched, observational study of COVID-19, intermediate-dose anticoagulation and aspirin were each associated with a lower cumulative incidence of in-hospital death., Competing Interests: Summary conflict of interest statements: No conflict of interest exists for any author on this manuscript.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results